May 2007
Volume 48, Issue 13
ARVO Annual Meeting Abstract  |   May 2007
A Phase 1 Clinical Study of 4-Methylpyrazole (4-MP) as a Potential Dark Adaptation Inhibitor for the Long-Term Treatment of Stargardt Disease and Geographic Atrophy
Author Affiliations & Notes
  • C. D. Jurgensmeier
    University of Utah, Salt Lake City, Utah
  • P. Bhosale
    University of Utah, Salt Lake City, Utah
  • P. S. Bernstein
    University of Utah, Salt Lake City, Utah
  • Footnotes
    Commercial Relationships C.D. Jurgensmeier, None; P. Bhosale, None; P.S. Bernstein, None.
  • Footnotes
    Support Macula Society study grant, Supplies donated by Orphan Medical
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 3677. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      C. D. Jurgensmeier, P. Bhosale, P. S. Bernstein; A Phase 1 Clinical Study of 4-Methylpyrazole (4-MP) as a Potential Dark Adaptation Inhibitor for the Long-Term Treatment of Stargardt Disease and Geographic Atrophy. Invest. Ophthalmol. Vis. Sci. 2007;48(13):3677.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose:: A number of research groups are currently developing novel pharmaceutical agents for Stargardt disease and geographic atrophy that decrease lipofuscin accumulation by inhibiting enzymes of the vertebrate visual cycle, but these drugs are either not yet approved for human use, or they have significant long-term side effects. 4-Methylpyrazole (4-MP) is another appealing possible pharmacological therapy for these disorders due to its known inhibition of the visual cycle in rodents, its lack of toxicity in long-term administration, and its FDA approval as an alcohol dehydrogenase inhibitor for the treatment of ethylene glycol and methanol poisoning in humans. It is unknown whether inhibition of dark adaptation comparable to that seen in rodents also occurs in humans receiving 4-MP.

Methods:: In a randomized, double-blind, phase 1 clinical trial, adults ≥18 years old who had no significant ocular pathologies were given intravenous infusions of either 4-MP (15 mg/kg) or placebo for a total of three infusions of each during six weekly visits. A blood sample was drawn from the opposite arm and tested by HPLC to assure therapeutic levels were attained. Dark adaptation was assessed by Goldmann-Weekers adaptometry, and results were quantified and transferred to statistical software.

Results:: Nine participants served as their own controls. Each participant demonstrated a linear, rod and cone mediated, log-based response during the initial phase of dark adaptation (roughly 7-10 mins) during both placebo and 4-MP sessions. Comparison of these results showed that at the α = 0.05 level, there were no statistically significant differences between the linear slopes of the 4-MP and placebo testing sessions.

Conclusions:: 4-MP does not appear to be a sufficient inhibitor of the human visual cycle to be considered further as a treatment for Stargardt disease or similar ocular disorders.

Clinical Trial:: NCT00346853

Keywords: retina • degenerations/dystrophies • drug toxicity/drug effects 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.